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Edited by Stuart FergusonAbstract Fibroblast activation protein (FAP) is a serine
protease of undeﬁned endopeptidase speciﬁcity implicated in
tumorigenesis. To characterize FAP’s P4–P
0
2 speciﬁcity, we syn-
thesized intramolecularly quenched ﬂuorescent substrate sets
based on the FAP cleavage site in a2-antiplasmin (TSGP-NQ).
FAP required substrates with Pro at P1 and Gly or D-amino
acids at P2 and preferred small, uncharged amino acids at P3,
but tolerated most amino acids at P4, P
0
1 and P
0
2. These substrate
preferences allowed design of peptidyl-chloromethyl ketones that
inhibited FAP, but not the related protease, dipeptidyl peptidase-
4. Thus, FAP is a narrow speciﬁcity endopeptidase and this can
be exploited for inhibitor design.
 2006 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Fibroblast activation protein (FAP) was initially identiﬁed
as the antigen recognized by monoclonal antibody F19 [1],
an antibody that binds ‘‘activated’’ ﬁbroblasts from cancer-
associated stroma and healing wounds. Goldstein et al. [2]
independently identiﬁed FAP as a serine protease (seprase)
potentially involved in melanoma invasion. Subsequent studies
suggest that FAP promotes tumorigenesis [3–5] and that FAP
inhibition may attenuate tumor growth [5], making this prote-
ase a potential therapeutic target. However, FAP substrates
potentially involved in tumorigenesis have not been identiﬁed,
and the protease’s substrate speciﬁcity has not been fully
characterized.
FAP is a type II trans-membrane serine protease belonging
to the prolyl peptidase family [1,2], a protease family with
strong preference for proline in the P1 position of substrates
[6]. Like its most closely related family member, dipeptidylAbbreviations: FAP, ﬁbroblast activation protein; DPP-4, dipeptidyl
peptidase-4; POP, prolyl oligopeptidase; a2AP, a2-antiplasmin; cmk,
chloromethyl ketone; AFC, 7-amino-4-triﬂuoromethyl coumarin;
Ac, acetyl; EDANS, 5-[(2-Aminoethyl)amino]naphthalene-1-sulfonic
acid; Dabcyl, 4-(4-Dimethylaminophenylazo)benzoyl; Abz, o-amino-
benzoyl; MALDI, matrix assisted laser-desorption ionization
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doi:10.1016/j.febslet.2006.01.087peptidase-4 (DPP-4), the extracellular portion of FAP contains
an N-terminal b-propeller domain and a C-terminal ab-hydro-
lase domain. The b-propeller has several potential sites of
N-linked glycosylation and follows a 20 amino acid transmem-
brane domain and six amino acid cytoplasmic tail. Crystallo-
graphic data for FAP [7] and DPP-4 [8–11] suggest that the
b-propeller domain as well as the ab-hydrolase domain contain
important substrate-binding sites and that key substrate-bind-
ing residues in both proteases are in very similar positions.
However, an Ala residue (A657) located near FAP’s S2 pocket,
instead of an Asp residue (D663) as in DPP-4, allows FAP to
act as both a dipeptidyl peptidase and endopeptidase [7]. In
contrast, D663 limits DPP-4 activity in a manner that allows
only dipeptidyl peptidase activity [7].
Endogenous FAP dipeptidyl peptidase substrates are un-
known; however, results with coumarin-based dipeptide sub-
strates show that FAP cleaves P2-Pro1-coumarins with broad
P2 speciﬁcity [12–14] and N-acyl-P2-Pro1-coumarins with a P2
Gly residue [7,14]. FAP has known endopeptidase activity that
cleaves the Pro12–Asn13 bond of a2-antiplasmin (a2AP) [15],
but the full spectrum of FAP’s endopeptidase speciﬁcity is un-
known. Herein, we deﬁned FAP’s P4–P
0
2 speciﬁcity using intra-
molecularly quenched ﬂuorescent substrates based on the FAP
cleavage site in a2-AP. We found that FAP requires substrates
with Pro at P1 and Gly (or D-amino acids) at P2, but has
broader tolerance at the P3, P4, P
0
1 and P
0
2 positions. These sub-
strate preferences allowed design of peptidyl-chloromethyl ke-
tones (cmk) that inhibited FAP, but not DPP-4. Thus, FAP is
a Gly-Pro-cleaving endopeptidase and its narrow speciﬁcity
can be exploited for inhibitor design.2. Materials and methods
2.1. Substrates
Amino acid derivatives were from Novabiochem. D-ala-Pro-7-ami-
no-4-triﬂuoromethyl coumarin (AFC) and acetyl (Ac)-D-ala-Pro-
AFC were from Enzyme Systems Products. Ac-Gly-Pro-cmk and
Ac-Thr-Ser-Gly-Pro-cmk were custom synthesized by Anaspec. Intra-
molecularly quenched ﬂuorescent peptide substrates were prepared by
solid phase synthesis, puriﬁed by reverse phase chromatography and
veriﬁed by matrix assisted laser-desorption ionization (MALDI)-mass
spectrometry [16]. To identify substrate cleavage sites, we incubated
substrates (10 lM) with FAP (10 nM) for 18 h at 23 C in 50 mM Tris
(pH 7.4), 100 mM NaCl, 1 mM EDTA (assay buﬀer) and then ana-
lyzed the products by Edman degradation [17] or MALDI-mass spec-
trometry [18].blished by Elsevier B.V. All rights reserved.
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Soluble, N-terminally FLAG-tagged FAP (amino acids 38–760) and
DPP-4 (amino acids 39–766) were expressed in 293 HEK cells and
puriﬁed by aﬃnity chromatography using M2 anti-FLAG-agarose
beads (Sigma) [14]. Protease preparations were >95% pure as deter-
mined by SDS–PAGE with Coomassie staining and contained >90%
dimer when analyzed by gel ﬁltration chromatography and multi-angle
light scattering [19]. The dimeric fraction was considered the propor-
tion of active protease in each preparation.
2.3. Protease assays
Protease activity was monitored continuously using a SpectraMax
M2 microplate reader (Molecular Devices) in the kinetic mode. Assays
were conducted at 23 C in assay buﬀer containing 0.1 mg/ml bovine
serum albumin. The excitation/emission wavelengths were 340/
510 nm for 5-[(2-aminoethyl)amino]naphthalene-1-sulfonic acid
(EDANS), 337/420 nm for o-aminobenzoyl (Abz)-Gly and 400/
505 nm for AFC. Standard curves of the appropriate ﬂuorescent prod-
uct versus concentration were used to convert relative ﬂuorescence
units to mol of product produced. Kinetic constants (kcat, Km) were
determined with initial rate measurements using substrate concentra-
tions in the range of 0.1–5 Km value and 10–30 nM FAP. Kinetic
parameters were calculated fromMichaelis–Menten plots with non-lin-
ear regression analysis using GraphPad software. Correlation coeﬃ-
cients (r2) for the non-linear regression analyses were >0.93. Data
represent the average ± SEM of three independent experiments.
2.4. Inhibition assays
To study concentration-dependent inhibition, Ac-Gly-Pro-cmk and
Thr-Ser-Gly-Pro-cmk (10–500 lM) were incubated with proteases
(160 nM) at 37 C in assay buﬀer. After 6 h, residual protease activity
against Ala-Pro-AFC was determined. In control studies, inhibitors
were pre-incubated in assay buﬀer for various times up to 6 h at
37 C prior to reaction with FAP. We observed no loss of inhibitory
activity following the pre-incubation, indicating that the inhibitors
were stable under our assay conditions.
To conﬁrm that Ac-Gly-Pro-cmk and Thr-Ser-Gly-Pro-cmk acted
irreversibly, FAP (0.2 lM) was incubated alone or with each inhibitor
(100 lM) for 18 h at 37 C in assay buﬀer. Residual FAP activity
against Ala-Pro-AFC was then assessed before and after the reaction
mixtures were dialyzed extensively against assay buﬀer.
Time-dependent inhibition of FAP was studied under pseudo-ﬁrst-
order conditions and modeled to the following inhibition scheme:
Eþ I¡k1
k1
EI!k2 EI
KI ¼ ½E½I½EI
where E is the enzyme, I is the inhibitor, EI is a reversible enzyme–
inhibitor complex, EI* is the covalent enzyme–inhibitor complex, KI
is the dissociation constant for the EI complex and k2 is the limiting
rate constant of inactivation [20]. Brieﬂy, FAP (160 nM) was incubated
with Ac-Gly-Pro-cmk or Thr-Ser-Gly-Pro-cmk (50–1000 lM) at 37 C
in assay buﬀer. Samples were withdrawn at the indicated times and
residual protease activity against Ala-Pro-AFC was determined. Data
were ﬁt according to ﬁrst-order conditions for depletion of enzyme by
the inhibitor using the equation ln (E/ET) = kobst, where E/ET repre-
sents the residual enzyme activity and kobs is the observed pseudo-ﬁrst-
order inactivation rate constant. Plots of ln (E/ET) versus time were
linear and kobs values were calculated from the slopes. When
[I] [E], kobs = k2[I]/(KI + [I]), which allows calculation of KI and k2
from plots of 1/kobs versus 1/[I] using the following linear relationship:
1/kobs = (KI/k2[I]) + 1/k2 [20].
3. Results and discussion
3.1. Substrate design
Lee et al. [15], recently reported that FAP cleaves an intra-
molecularly quenched ﬂuorescence substrate based on the
FAP cleavage site in a2AP, suggesting that such peptide sub-
strates might be used to characterize FAP’s endopeptidase
speciﬁcity. We therefore designed substrate sets based on theFAP cleavage site in a2AP, which contain a ﬂuorogenic
EDANS group and a quenching 4-(4-dimethylaminopheny-
lazo)benzoyl (Dabcyl) group that brackets the P4–P
0
4 residues
of the a2AP cleavage site [15], with P1–P
0
1 representing the scis-
sile bond, Pn+1 substrate residues N-terminal to the scissile
bond and P0nþ1 residues C-terminal to the scissile bond [21].
TSGP-NQEQ is the parental P4–P
0
4 sequence and hydrolysis
occurs between the P1 Pro residue and the P
0
1 Asn residue. Sub-
strate hydrolysis separates EDANS from the nearby Dabcyl,
generating a ﬂuorescent signal that can be monitored spectro-
ﬂuorimetrically. We focused on the P4–P
0
2 substrate residues,
as crystallographic data for FAP and DPP-4 suggests that
these are important for substrate recognition [7–11]. Thus,
the parental sequence was varied systematically in each frame
to characterize FAP’s P4–P
0
2 speciﬁcity. The speciﬁc substrate
sets synthesized were:
RK(Dabcyl)TSGP1-NQEQE(EDANS)R for P1;
RK(Dabcyl)TSP2P-NQEQE(EDANS)R for P2;
RK(Dabcyl)TP3GP-NQEQE(EDANS)R for P3;
RK(Dabcyl)P4SGP-NQEQE(EDANS)R for P4;
RK(Dabcyl)TSGP-P01QEQE(EDANS)R for P
0
1; and
RK(Dabcyl)TSGP-NP02EQE(EDANS)R for P
0
2.
The italicized substrate residue was varied with representa-
tive amino acids containing aliphatic, aromatic, basic, acidic,
hydroxyl, or amide side chains.3.2. FAP P4–P
0
2 substrate speciﬁcity
Fig. 1 shows the results for cleavage of the P4–P
0
2 substrate
sets by FAP. FAP required Pro at P1 (Fig. 1A), having no mea-
surable activity against all other substrates in this series. Strik-
ingly, FAP also showed marked restriction in P2 speciﬁcity
(Fig. 1B), cleaving only the substrate with a P2 Gly residue.
Taken together, the data suggest that FAP prefers endopepti-
dase substrates containing a Gly2-Pro1 motif.
In the P3 position, FAP cleaved P3-Ala and P3-Ser substrates
most eﬃciently (Fig. 1C). Less activity was observed against
charged and aromatic amino acid residues, suggesting a prefer-
ence for small, uncharged amino acids at P3. FAP favored Ala
in the P4 position (Fig. 1D); however, all substrates were
cleaved in this series at 25–130% of the rate for cleavage of
the parental substrate, indicating that FAP has broader speci-
ﬁcity at this position.
Less restricted speciﬁcity was also observed at P01 and P
0
2,
with FAP cleaving all substrates in these series. A moderate
preference for substrates with Ala, Asn, or Ser was observed
at P01, but this was less prominent at P
0
2. With both substrate
sets, FAP showed less activity against Asp-, His-, Lys-, and
Leu-containing substrates, suggesting less tolerance for these
residues at P01 and P
0
2.3.3. Kinetic constants for preferred substrates
We next determined kinetic parameters for cleavage of the
preferred substrate in each frame by FAP (Table 1). For com-
parison, we also synthesized and studied a composite substrate
representing the optimal amino acid preferences in each frame.
Surprisingly, the Km value for cleavage of the composite sub-
strate was 3.3-fold higher than the parental substrate (Table
1). However, a concomitant 3.4-fold increase in kcat was ob-
served with the composite substrate, yielding a nearly equiva-
lent catalytic eﬃciency (kcat/Km) for each substrate. The
catalytic eﬃciencies for cleavage of the P4-Ala, P3-Ala, P
0
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Fig. 1. FAP P4–P
0
2 substrate speciﬁcity. The parental sequence of the FAP a2AP cleavage site (TSGP-NQ) was varied systematically in each frame to
generate P4–P
0
2 substrate sets as described in the text. The varied frame is indicated at top right of each graph and the parental amino acid in each
frame is underlined. Initial rates of substrate hydrolysis (1 lM substrate, 10 nM enzyme) relative to the parental substrate are indicated on the Y-axis
of each graph. The varied amino acid is listed on the X-axis of each graph in single letter code.
Table 1
Kinetic constants for hydrolysis of preferred a2AP-derived peptide
substrates by FAP
Peptide P4–P
0
2 sequence
a Km (lM) kcat (s
1) kcat/Km
(M1 s1)
Parental TSGP-NQ 1.3 ± 0.1 1.6 ± 0.1 1.2 · 106
P4-Ala ASGP-NQ 2.2 ± 0.2 2.7 ± 0.2 1.2 · 106
P3-Ala TAGP-NQ 0.7 ± 0.1 1.5 ± 0.1 2.1 · 106
P01-Ser TSGP-SQ 1.9 ± 0.2 2.0 ± 0.1 1.1 · 10
6
P02-Ser TSGP-NS 2.2 ± 0.3 3.1 ± 0.2 1.4 · 10
6
Composite ASGP-SS 4.3 ± 0.3 5.5 ± 0.3 1.3 · 106
aAll cleavages occurred following the P1 Pro residue as determined by
MALDI-mass spectrometry or N-terminal sequencing.
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tal substrate, reﬂecting Km and kcat values that diﬀered less
than twofold from the parental values. This suggests that the
core Gly-Pro residues present in each substrate at P2 and P1
are critical determinants of FAP catalytic eﬃciency.
3.4. FAP activity against additional proline-containing
endopeptidase substrates
To extend the preceding results, we next examined FAP’s
activity against additional proline-containing endopeptidasesubstrates. For this, we tested three commercially available
substrates (Met-Gly-Pro-AFC, pyroGlu-His-Pro-AFC, renin
substrate) and synthesized an octapeptide substrate cleaved
by prolyl oligopeptidase (POP) [22]. Renin substrate and the
POP octamer are intramolecularly quenched ﬂuorescent sub-
strates, whereas, the Met-Gly-Pro- and pyroGlu-His-Pro-sub-
strates contain the ﬂuorescent leaving group AFC. FAP
readily cleaved Met-Gly-Pro-AFC and the POP octamer,
which contain the Gly2-Pro1 motif, but showed no activity
against pyroGlu-His-Pro-AFC or renin substrate, which lack
this motif (Table 2). Met-Gly-Pro-AFC was cleaved less eﬃ-
ciently than the POP octamer, reﬂecting a large increase in
the Km value for the tripeptide substrate. Together with the
preceding results, these data suggest that FAP requires the
Gly2-Pro1 motif for cleavage of endopeptidase substrates.
3.5. FAP activity against substrates containing D-amino acids at
position P2
FAP’s strict requirement for Gly in the P2 position of sub-
strates is particularly intriguing because glycine is fundamen-
tally diﬀerent from L-amino acids as it lacks a side chain and
often adopts a positive phi value in the Ramachandran plot
[23]. Since D-amino acids can often replace glycine, we tested
Table 3
Kinetic constants for hydrolysis of substrates containing P2 D-amino
acids by FAP
Substrate Km (lM) kcat (s
1) kcat/Km (M
1 s1)
P2 D-ala a2AP
a,c 0.8 ± 0.1 0.19 ± 0.02 2.4 · 105
P2 D-ser a2AP
b,c 0.6 ± 0.1 0.22 ± 0.044 3.7 · 105
D-ala-Pro-AFC 541 ± 120 0.30 ± 0.05 461
Ac-D-ala-Pro-AFC 213 ± 22 1.5 ± 0.1 7.2 · 103
aP2 D-ala a2AP, RK(Dabcyl)TS-D-ala-PNQEQE(Edans)R.
bP2 D-ser a2AP, RK(Dabcyl)TS-D-ser-PNQEQE(Edans)R.
cSequence analysis conﬁrmed that cleavage occurred following the P1
Pro residue.
Table 2
Kinetic constants for hydrolysis of Pro-containing peptide substrates
by FAP
Substrate Km (lM) kcat (s
1) kcat/Km (M
1 s1)
MGP-AFC 142 ± 11 2.2 ± 0.2 1.5 · 104
pyroEHP-AFC NCa NC NC
Renin substrateb NC NC NC
POP octamerc 5.9 ± 0.9 2.1 ± 0.3 3.6 · 105
aNC, no cleavage.
bRenin substrate, RE(Edans)IHPFHLVLHTK(Dabcyl)R.
cPOP octamer, Abz-GFGPFGF(NO2)A-NH2; cleavage occurred fol-
lowing the P1 Pro residue as determined by MALDI-mass spectrom-
etry.
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D-amino acid in the P2 position. For this, we synthesized intra-
molecularly quenched ﬂuorescent substrates based on the
parental a2-AP peptide, but containing D-ala or D-ser instead
of Gly at P2. FAP cleaved both substrates, with kinetic param-
eters as listed in Table 3. The kcat values for hydrolysis of the
P2 D-amino acid substrates were about eightfold lower thanA
C
E
Fig. 2. FAP inhibition based on endopeptidase speciﬁcity. FAP and DPP-4
and Thr-Ser-Gly-Pro-cmk (B) and residual protease activity was measured a
Thr-Ser-Gly-Pro-cmk (D) under pseudo-ﬁrst-order conditions (m 50 lM, . 1
inactivation monitored with time as described in the text. Pseudo-ﬁrst-order
plots and used to construct plots of 1/kobs versus 1/[I] as shown in (E) and (the parental substrate with a P2 Gly (Table 1); however, the
Km values were 2-fold lower than the Km for the parental
peptide (Table 1), resulting in a three to ﬁvefold decrease in
catalytic eﬃciency (Table 3). FAP also cleaved dipeptidyl
peptidase substrates with D-ala in the P2 position, although
this was less eﬃcient due to a large increase in Km relative to
the D-ala and D-ser endopeptidase substrates (Table 3). Thus,B
D
F
were incubated with increasing concentrations of Ac-Gly-Pro-cmk (A)
gainst Ala-Pro-AFC. FAP was incubated with Ac-Gly-Pro-cmk (C) or
00 lM,¤ 250 lM, d 500 lM and n 1000 lM inhibitor) and protease
inactivation constants (kobs) were determined from the slopes of these
F).
Fig. 3. FAP substrate binding model. The model shows a peptide with
the P3–P
0
1 sequence Ser-D-ala-Pro-Ile bound to FAP. The crystal
structure of DPP-4 in complex with diprotin A was used as a starting
point to model the peptide (pdb accession code 1NU8). The surface
depicts the structure of FAP (pdb accession code 1Z68) with carbons
shown in white, oxygens in red, and nitrogens in blue. The carbon
atoms of the peptide are in yellow and the side chain of the P2 D-ala
residue is highlighted in cyan.
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at P2.
3.6. FAP inhibition based on endopeptidase speciﬁcity
FAP’s endopeptidase activity distinguishes the protease
from its most closely related family member, DPP-4, which
functions solely as a dipeptidyl peptidase [6]. We therefore
hypothesized that inhibitors based on FAP’s endopeptidase
substrate preferences might inhibit FAP but not DPP-4. To
test this, we synthesized and tested two inhibitors, Ac-Gly-
Pro-cmk and Thr-Ser-Gly-Pro-cmk, which coupled the Gly2-
Pro1 speciﬁcity motif to a cmk moiety capable of reacting with
the protease’s active site. Increasing concentrations of each
inhibitor progressively decreased FAP activity; however, nei-
ther inhibited DPP-4 even at concentrations of 500 lM
(Fig. 2A and B). Moreover, incubation of FAP with each
inhibitor (100 lM) overnight resulted in complete inactivation
of the protease. No activity was recovered when the inhibitors
were removed by dialysis, indicating that Ac-Gly-Pro-cmk and
Thr-Ser-Gly-Pro-cmk inhibit FAP irreversibly.
In kinetic experiments, Ac-Gly-Pro-cmk and Thr-Ser-Gly-
Pro-cmk inactivated FAP in a concentration-dependent man-
ner that followed pseudo-ﬁrst-order kinetics as shown in
Fig. 2C and D. The pseudo-ﬁrst-order inactivation rate con-
stants (kobs) determined in these experiments were used to con-
struct plots of 1/kobs versus 1/[I] (Fig. 2E and F), which
allowed determination of k2, the limiting rate constant of inac-
tivation and KI, the dissociation constant for the reversible en-
zyme–inhibitor complex. The values obtained for FAP
inhibition by Ac-Gly-Pro-cmk were k2 = 0.017 min
1 and
KI = 156 lM and those for Thr-Ser-Gly-Pro-cmk were k2 =
0.022 min1 and KI = 218 lM. These data suggest that each
inhibitor forms a low aﬃnity reversible complex with FAP that
slowly converts to an irreversible FAP–inhibitor complex. The
FAP-related prolyl peptidases, acyl peptide hydrolase [24] and
POP [25], are also inactivated slowly by peptidyl-cmk inhibi-
tors, suggesting that slow reaction with peptidyl-cmks is a
property of this enzyme family.
3.7. FAP speciﬁcity model
In summary, we have deﬁned FAP as an endopeptidase of
Gly2-Pro1-cleaving speciﬁcity and developed inhibitors based
on this speciﬁcity that show selectivity for FAP versus DPP-
4. The structural model presented in Fig. 3 suggests a mecha-
nism for this speciﬁcity and explains why D-amino acids can
replace Gly at P2. As shown in the model, FAP contains a
well-deﬁned, hydrophobic S1 binding pocket that best accom-
modates substrates with a P1 Pro residue. Beyond P1, the model
predicts that substrates must contain a small amino acid able
to adopt a positive phi value in the Ramachandran plot to
avoid steric clashes between the protease and the P3 residue
side chain and the P3 residue’s carbonyl group. Glycine is
the only natural amino acid that meets both criteria, which ex-
plains the observed P2 speciﬁcity. Small D-amino acids may re-
place Gly at P2 as shown in the model, explaining FAP’s
activity against substrates containing D-ala or D-ser at P2.
The model also suggests that small amino acids will be pre-
ferred at P3 to avoid clashes with protease residues, as was ob-
served with the P3 substrate set. The substrate speciﬁcity data
and structural model we report here provide insight into how
FAP binds substrates and establish a framework for FAP-
inhibitor design.References
[1] Scanlan, M.J., Mohan, B.K.M., Calvo, B., Garin-Chesa, P., Sanz-
Moncasi, M.P., Healey, J.H., Old, L.J. and Rettig, W.J. (1994)
Molecular cloning of ﬁbroblast activation protein alpha, a
member of the serine protease family selectively expressed in
stromal ﬁbroblasts of epithelial cancers. Proc. Natl. Acad. Sci.
USA 91, 5657–5661.
[2] Goldstein, L., Ghersi, G., Pineiro-Sanchez, M., Salamone, M.,
Yeh, Y., Flessate, D. and Chen, W.-T. (1997) Molecular cloning
of seprase: a serine integral membrane protease from human
melanoma. Biochim. Biophys. Acta 1361, 11–19.
[3] Cheng, J.D., Dunbrack, R.L., Valianou, M., Rogarto, A.,
Aplaugh, R.K. and Weiner, L.M. (2002) Promotion of tumor
growth by murine ﬁbroblast activation protein, a serine protease,
in an animal model. Cancer Res. 62, 4767–4772.
[4] Huang, Y., Wang, S. and Kelly, T. (2004) Seprase promotes rapid
tumor growth and increased microvessel density in a mouse model
of human breast cancer. Cancer Res. 64, 2712–2716.
[5] Cheng, J.D., Valianou, M., Canutescu, A.A., Jaﬀe, E.K., Lee, H.-
O., Wang, H., Lai, J.H., Bachovchin, W.W. and Weiner, L.M.
(2005) Abrogation of ﬁbroblast activation protein enzymatic
activity attenuates tumor growth. Mol. Cancer Ther. 4, 351–360.
[6] Rosenblum, J.S. and Kozarich, J.W. (2003) Prolyl peptidases: a
serine protease subfamily with high potential for drug discovery.
Curr. Opin. Chem. Biol. 7, 496–504.
[7] Aertgeerts, K., Levin, I., Shi, L., Snell, G.P., Jennings, A., Prasad,
G.S., Zhang, Y., Kraus, M.L., Salakian, S., Sridhar, V., Wijn-
ands, R. and Tennant, M.G. (2005) Structural and kinetic analysis
of the substrate speciﬁcity of human ﬁbroblast activation protein
alpha. J. Biol. Chem. 280, 19441–19444.
[8] Engel, M., Hoﬀmann, T., Wagner, L., Wermann, M., Heiser, U.,
Kiefersauer, R., Huber, R., Bode, W., Demuth, H.-U. and
Brandstetter, H. (2003) The crystal structure of dipeptidyl
peptidase IV (CD26) reveals its functional regulation and
enzymatic mechanism. Proc. Natl. Acad. Sci. USA 100, 5063–
5068.
[9] Rasmussen, H.B., Branner, S., Wiberg, F.C. and Wagtmann,
N. (2003) Crystal structure of human dipeptidyl peptidase IV/
CD26 in complex with a substrate analog. Nat. Struct. Biol. 10,
19–25.
[10] Thoma, R., Loﬄer, B., Stihle, M., Huber, W., Ruf, A. and
Henning, M. (2003) Structural basis of proline-speciﬁc exopepti-
dase activity as observed in human dipeptidyl peptidase-IV.
Structure 11, 947–959.
1586 C.Y. Edosada et al. / FEBS Letters 580 (2006) 1581–1586[11] Hiramatsu, H., Yamamotoa, A., Higashiyama, Y., Fukushima,
C., Shima, H., Sugiyama, S., Inaka, K. and Shimizu, R. (2004)
The crystal structure of human dipeptidyl peptidase IV (DPPIV)
complex with diprotin A. Biol. Chem. 385, 561–564.
[12] Huber, M.A., Kraut, N., Park, J.E., Schubert, R.D., Rettig, W.J.,
Peter, R.U. and Garin-Chesa, P. (2003) Fibroblast activation
protein: diﬀerential expression and serine protease activity in
reactive stromal ﬁbroblasts of melanocytic tumors. J. Invest.
Dermatol. 120.
[13] Levy, M., McCaughan, G., Abbott, C., Park, J.E., Cunningham,
A., Muller, E., Rettig, W.J. and Gorrell, M. (1999) Fibroblast
activation protein: a cell surface dipeptidyl peptidase and
gelatinase expressed by stellate cells at the tissue remodeling
interface in human cirrhosis. Hepatology 29, 1768–1778.
[14] Edosada, C., Quan, C., Wiesmann, C., Tran, T., Sutherlin, D.,
Reynolds, M., Elliott, J., Raab, H., Fairbrother, W. and Wolf, B.
(2006) Selective inhibition of ﬁbroblast activation protein prote-
ase based on dipeptide substrate speciﬁcity. J. Biol. Chem. [Epub
ahead of print].
[15] Lee, K., Jackson, K., Christiansen, V., Chung, K. and McKee, P.
(2004) A novel plasma proteinase potentiates alpha-2-antiplasmin
inhibition of ﬁbrin digestion. Blood 103, 3783–3788.
[16] Atherton, E., Brown, E., Priestly, G., Sheppard, R. and Williams,
B. (1981) Fmoc Solid Phase Synthesis, APS, Rockford.[17] Henzel, W., Tropea, J. and Dupont, D. (1999) Protein identiﬁ-
cation using 20-minute Edman cycles and sequence mixture
analysis. Anal. Biochem. 267, 148–160.
[18] Pham, V., Henzel, W. and Lill, J. (2005) Rapid on-membrane
proteolytic cleavage for Edman sequencing and mass spectromet-
ric identiﬁcation of proteins. Electrophoresis 26, 4243–4251.
[19] Mogridge, J. (2004) Using light scattering to determine the
stoichiometry of protein complexes. Methods Mol. Biol. 261, 113–
118.
[20] Powers, J. (1977) Reaction of serine proteases with halomethyl
ketones. Methods Enzymol. 46, 197–208.
[21] Schechter, I. and Berger, M. (1967) On the size of the active site in
proteases. Biochem. Biophys. Res. Commun. 27, 157–162.
[22] Fulop, V., Szeltner, Z., Renner, V. and Polgar, L. (2001)
Structures of prolyl oligopeptidase substrate/inhibitor complexes.
J. Biol. Chem. 276, 1262–1266.
[23] Ho, B. and Brasseur, R. (2005) The Ramachandran plots of
glycine and pre-proline. BMC Struct. Biol. 5, 1–11.
[24] Kobayashi, K. and Smith, J. (1987) Acyl-peptide hydrolase from
rat liver, characterization of enzyme reaction. J. Biol. Chem. 262,
11435–11445.
[25] Yoshimoto, T., Orlowski, R. and Walter, R. (1977) Postproline
cleaving enzyme: identiﬁcation as a serine protease using active
site speciﬁc inhibitors. Biochemistry 16, 2942–2948.
